WEST PALM BEACH, Fla.
April 2, 2013
/PRNewswire/ -- FTI Consulting, Inc. (NYSE: FCN), the global business advisory firm dedicated to helping organizations protect and enhance their enterprise value, today announced that
has been appointed Managing Director in the firm's Strategic Communications practice.
The addition of Ms. Ryan, a recognized biopharmaceutical industry expert and veteran Wall Street professional, further strengthens the practice's financial communications capabilities and deepens its expertise in the healthcare and life sciences sector. In her new role, Ms. Ryan will also support the firm's healthcare and life sciences transactions communications and crisis communications offerings. She will be based in New York.
Ms. Ryan brings more than 30 years of Wall Street experience and financial expertise, with a focus in the biopharmaceutical sector, to FTI Consulting. She joins the firm from Deutsche Bank, where she held the position of Managing Director and Head of the Pharmaceutical Research Team for the past 20 years. In this role, Ms. Ryan published pharmaceutical research, led the firm's annual healthcare conference and conducted extensive marketing activities with institutional clients. She also served as the lead analyst on several high-profile initial public offerings. Prior to joining Deutsche Bank, Ms. Ryan held pharmaceutical analyst positions at Prudential Securities and Bear Sterns. Ms. Ryan frequently is a guest contributor to CNBC.
"Barbara is an exciting addition to our thriving healthcare and life sciences sector," said
, Global Chief Executive Officer of the FTI Consulting Strategic Communications practice. "Barbara is a well-known and well-respected voice in the healthcare industry with a deep understanding of how investors think about and value stocks. Our clients will undoubtedly benefit from her valuable perspective and insight as they face critical times of corporate growth and transformation."
Ms. Ryan added, "FTI Consulting is a clear leader in healthcare strategic communications, and I am excited to join such a dynamic and growing practice. I look forward to utilizing my many years of experience on Wall Street covering the pharmaceutical industry to further advance the firm's healthcare and life sciences capital markets offering."